InterveXion has been awarded a two year $3.9 million grant entitled “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity” by the National Institutes of Health, National Institute on Drug Abuse (NIDA) as part of the American Recovery and Reinvestment Act of 2009. W. Brooks Gentry, M.D. and R. Barry Holtz, Ph.D. are the principal investigators. Their application was selected from a highly competitive pool and awards were given to institutions and companies that could show that the funds would accelerate programs toward a major milestone or commercialization endpoint. The funds will be used to move the methamphetamine mAb product toward the clinic by developing the large-scale manufacturing process, conducting IND-enabling toxicology testing, and completing the clinical preparations. By the end of the funding period, InterveXion will be ready for a Phase I clinical trial.
- Methamphetamine impairs IgG1-mediated phagocytosis and killing of Cryptococcus neoformans by J774.16 macrophage- and NR-9640-microglia-like cells | Infection and Immunity
- Increase in Methamphetamine Use by Iowans (11/26/18)
- U.S. GAO – Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and Recovery Services and for Research
- Meth Use On The Rise Among Pregnant Women : Shots – Health News : NPR
- Methamphetamine: A Regional Drug Crisis | NDEWS l National Drug Early Warning System l University of Maryland